3-(2-norbornyl)propionic acid | 22637-41-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-(2-norbornyl)propionic acid
• 英文别名: β-heptyl-(2)>propionsaeure；β-(Bicyclo[2.2.1]heptyl-(2))propionsaeure；3-(2-bicyclo[2.2.1]heptanyl)propanoic acid
• CAS: 22637-41-8
• 化学式: C₁₀H₁₆O₂
• mdl: MFCD20641123
• 分子量: 168.236
• InChiKey: IFRPOCRJAZIRNB-UHFFFAOYSA-N

物化性质

• 沸点：
  279.6±8.0 °C(Predicted)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-norbornyl)propionic acid 在 铁粉 作用下， 生成 1,5-bis-(norborn-2-yl)pentan-3-one
  参考文献：
  名称：

  Antibacterial N-[.omega.,.omega.'-bis(alicyclic and aryl)-sec-alkyl]poly(methylenetriamine and -tetramine) hydrochloride salts

  摘要：

  A series of antibacterial N-(omega, omega'-(cycloalkyl, bicyclo[2.2.1]heptyl, and alkyl-substituted phenyl)-sec-alkyl]poly(methylene)triamine and -tetramine hydrochloride salts were synthesized in an effort to develop efficient, nonsystemic inhibitors, particularly for Pseudomonas aeruginosa. In the 1,5,9-triazanonane group, 3 of 16 compounds were effective at 8--10 micrograms/mL against pseudomonads. Efficiency appeared more dependent upon lipophilicity of the nitrogen substituent than other characteristics represented by the three types of rings. A parabolic relationship was observed for the entire set between the hydrophobic parameter, pi, of the lipoidal moiety and minimal inhibitory concentration. One of 16 tetramines, 1-[1,5-bis(3,3-dimethyl-2-norbornyl)-3-pentyl]-1,5,9,13-tetraazatridecane tetrahydrochloride (26f), ranked similarly. An additional two compounds in each series were superior to several commercial cationic detergents in the control of the Gram-negative bacteria. None was inhibitory at up to 200 micrograms/mL for Proteus vulgaris.

  DOI：

  10.1021/jm00197a024
• 作为产物：
  描述：

  5-降冰片烯-2-甲醛 在 platinum(IV) oxide 哌啶 、 氢气 作用下， 以 苯 为溶剂， 生成 3-(2-norbornyl)propionic acid
  参考文献：
  名称：

  Kasper,F.; Kuschel,K., Journal fur praktische Chemie (Leipzig 1954), 1969, vol. 311, p. 97 - 101

  摘要：

  DOI：

文献信息

• 4-(4-imidazolyl) piperidines substituted at position 1, their
  申请人：National De La Sante et De La Recherche Medicale

  公开号：US05290790A1

  公开（公告）日：1994-03-01

  The compounds correspond to the general formula ##STR1## in which R.sub.1 represents a hydrogen atom or a group --COR.sub.2, in which R.sub.2 represents a benzene ring, cyclopentylmethyl, cyclohexylmethyl, cyclopentylethyl or cyclohexylethyl groups or cyclopentylamine, cyclohexylamine or phenylamine, chlorophenylamine or dichlorophenylamine groups; R represents a hydrogen atom or a group COR.sub.3, in which R.sub.3 represents an aliphatic group, a cyclane or benzene ring-system, a group a group (CH.sub.2).sup.m R.sub.4, a group --CH.dbd.CHR.sub.8 or a secondary amine group --NH(CH.sub.2).sub.n R.sub.g ; R also represents a hydroxyalkenyl group: ##STR2##

  这些化合物对应于一般公式##STR1##，其中R.sub.1代表氢原子或基团--COR.sub.2，其中R.sub.2代表苯环、环戊甲基、环己甲基、环戊基乙基或环己基乙基基团或环戊胺、环己胺或苯胺、氯苯胺或二氯苯胺基团；R代表氢原子或基团COR.sub.3，其中R.sub.3代表脂肪基、环己烷或苯环系统、基团(CH.sub.2).sup.m R.sub.4、基团--CH.dbd.CHR.sub.8或二级胺基团--NH(CH.sub.2).sub.n R.sub.g；R还表示羟基烯基基团：##STR2##
• 5-Fluorouracil derivatives, and their pharmaceutical compositions
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04349552A1

  公开（公告）日：1982-09-14

  A compound of the formula: ##STR1## wherein R is a bridged alicyclic group selected from the group consisting of norbornyl, norbornenyl, bicyclo[2,2,2]-heptyl and adamantyl optionally substituted by at least one substituent selected from the group consisting of lower alkyl, carboxy, lower alkoxycarbonyl, alkylidenedioxy, N,N-di(lower)alkylcarbamoyl, amino, loweralkoxycarbonylamino and halogen. The present compound is useful in the therapeutic treatment of cancer in human beings and animals.

  分子式为：##STR1## 其中R是从诺博烯基，诺博烯基，双环[2,2,2]-庚烷基和金刚烷基中选择的桥式脂环基，可以选择性地被至少一种取代基所取代，所述取代基选择自下列群体：低碳基，羧基，低碳基氧羰基，烷基二氧基，N，N-二（低）烷基氨基甲酰基，氨基，低碳基氧羰基氨基和卤素。该化合物在治疗人类和动物的癌症中有用。
• 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0010941A1

  公开（公告）日：1980-05-14

  The present invention provides compounds of the general formula:- wherein R is an optionally substituted bridged alicyclic radical or a substituted lower alkyl radical, the substituent being an optionally substituted bridged alicyclic group, an amino, protected amino, lower alkoxy, acyl, lower alkylthio, cyano(lower)alkylthio, arylthio or optionally substituted heterocyclic radical or a carboxy and esterified carboxy group, with the proviso, that when the substituent is a carboxy or esterified carboxy group then the lower alkyl radical contains 3 to 6 carbon atoms; or an unsubstituted or substituted lower alkenyl radical, the substituent being an optionally substituted bridged alicyclic group, an optionally substituted aryl radical or an optionally substituted heterocyclic radical; or a halophenyl radical; or an optionally substituted heterocyclic radical. 'The present invention also provides processes for the preparation of these compounds and pharmaceutical composition containing them. Furthermore, the present invention is concerned with a method of treating cancer which comprises administering these compounds to mammals suffering from cancer.

  本发明提供通式为：- 的化合物。 其中 R 是任选取代的桥式脂环基或取代的低级烷基，取代基是任选取代的桥式脂环基、氨基、保护氨基、低级烷氧基、酰基、低级烷硫基、氰基（低级）烷硫基、芳硫基或任选取代的杂环基或羧基和酯化羧基，但条件是当取代基是羧基或酯化羧基时，低级烷基含有 3 至 6 个碳原子；或未取代或取代的低级烯基，取代基为任选取代的桥式脂环基、任选取代的芳基或任选取代的杂环基；或卤代苯基；或任选取代的杂环基。 '本发明还提供了制备这些化合物和含有这些化合物的药物组合物的工艺。此外，本发明还涉及一种治疗癌症的方法，该方法包括对患有癌症的哺乳动物施用这些化合物。
• US4003934A
  申请人：——

  公开号：US4003934A

  公开（公告）日：1977-01-18
• US4058625A
  申请人：——

  公开号：US4058625A

  公开（公告）日：1977-11-15